Early treatment of patients with central serous retinopathy: A randomized controlled trial - CSR & PDT

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2009-017959-98-NL

Enrollment

Registered

2009-12-11

Start date

2010-03-25

Completion date

Unknown

Last updated

2022-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

central serous retinopathy

Interventions

Trade Name: Visudyne Product Name: verteporfine Product Code: verteporfine Pharmaceutical Form: Powder for infusion*

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Age > 18 years. Informed consent. Poor prognositic acute CSR Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: History of CSR in either eye. Allergy to fluorescein dyes. Allergy to visudyne. Opaque ocular media, impairing regular fundus imaging Other ocular disorder possibly reducing visual acuity

Design outcomes

Primary

Measure	Time frame
Main Objective: To determine the outcome in CSR patients comparing treatment with PDT versus observation.;Secondary Objective: NA;Primary end point(s): Visual acuity (BCVA ETDRS) at one year of follow up	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026